Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848983 | 0.78 | HDAC3 (0.50) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL20477546 | 0.76 | HDAC3 (0.53) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL2207597 | 0.74 | HDAC1 (0.75) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL20477567 | 0.74 | HDAC1 (0.56) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL25848982 | 0.74 | KMT2A (0.56) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL25848940 | 0.73 | LSS (0.50) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL24196677 | 0.72 | LSS (0.49) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL23135877 | 0.72 | HDAC3 (0.60) | HDAC3HDAC1HDAC6LSSMAPK14 | |
| SCHEMBL25849324 | 0.71 | PPARA (0.49) | HDAC3HDAC1HDAC4HDAC6LSS | |
| SCHEMBL24196671 | 0.70 | PPARA (0.49) | HDAC3HDAC1HDAC4HDAC6LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4175624-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-116075297-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | HDAC3 1223/4885HDAC1 1680/4885HDAC4 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.